THE WHAT? Kering has beat analyst expectations with its 2021 results, reporting annual revenues of €17.6bn, a 35 percent rise comparable to 2020, and 13 percent higher than pre-pandemic in 2019.
THE DETAILS The Gucci parent company reported a sharp rise of recurring operating income, which was up 60 percent relative to 2020, to reach a new record of €5,017 million. Recurring operating margin, at 28.4 percent, retrieved a high level.
Gucci enjoyed a profitable 2021, with revenue amounting to €9,731 million – up 31 percent both as reported and on a comparable basis. This exceeded the 2019 level even as the House neared completion of the streamlining of its wholesale operations.
Yves Saint Laurent’s 2021 revenue amounted to €2,521 million, an increase of 45 percent as reported and 46 percent on a comparable basis, while Bottega Veneta’s 2021 revenue exceeded €1.5 billion.
THE WHY? Growth was driven by outstanding performances from all Houses, according to Kering.
Looking forward, Kering looks to “achieve same-store revenue growth while ensuring the targeted and selective expansion of their retail networks.”
François-Henri Pinault, Chairman and Chief Executive Officer, said, “We expanded our team of talented people around the world, and I am sincerely grateful for the remarkable accomplishments of all our colleagues. We are working assiduously to meet our ambitious sustainability commitments. All our Houses are stronger than ever before, and we are confident we will extend last year’s momentum in 2022 and in coming years.”
Aesthetic injectable companies refer to businesses or companies that specialize in manufacturing, distributing, or providing aesthetic injectable products and services. These companies focus on developing and supplying injectable substances used for cosmetic purposes, typically administered by qualified medical professionals. Aesthetic injectable companies play a crucial role in the field of aesthetic medicine and cosmetic dermatology by offering a variety of injectable products designed to enhance facial features, reduce wrinkles, and improve overall skin appearance.
Key aspects of aesthetic injectable companies include:
-
Product Development: These companies research, develop, and manufacture aesthetic injectables such as dermal fillers, botulinum toxins (e.g., Botox), collagen stimulators, and other specialized formulations. They often innovate new products to meet evolving market demands and technological advancements.
-
Distribution and Sales: Aesthetic injectable companies distribute their products through authorized channels, including healthcare providers, medical spas, and aesthetic clinics. They may also sell directly to licensed professionals who administer these treatments.
-
Regulatory Compliance: Due to the medical nature of their products, aesthetic injectable companies adhere to strict regulatory guidelines and obtain necessary approvals from health authorities (e.g., FDA in the United States) to ensure safety, efficacy, and quality standards.
-
Training and Support: Many companies provide training and educational support to healthcare professionals on the proper use, administration techniques, and safety protocols associated with their injectable products. This ensures that practitioners can deliver treatments effectively and safely.
-
Customer Support: Aesthetic injectable companies offer customer support services to healthcare providers and consumers, addressing inquiries, providing product information, and assisting with product usage and troubleshooting.
